Angiodynamics Inc (ANGO) 16.54 $ANGO
47.2% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Wed Aug 31, 12:17AM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 6 months, Angiodynamics has returned 47.17% as of today's recent price of $16.77.
ANGO: 16.54 (-0.23)
Angiodynamics Shares Up 45.1% Since SmarTrend's Buy Recommendation (ANGO)
Comtex SmarTrend(R) - Tue Aug 23, 12:41PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 6 months, Angiodynamics has returned 45.06% as of today's recent price of $16.53.
ANGO: 16.54 (-0.23)
Angiodynamics Up 40.3% Since SmarTrend Uptrend Call (ANGO)
Comtex SmarTrend(R) - Tue Aug 16, 12:26AM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 5 months, Angiodynamics has returned 40.32% as of today's recent price of $15.99.
ANGO: 16.54 (-0.23)
AngioDynamics to Present at the 2016 Canaccord Genuity Growth Conference
GlobeNewswire - Mon Aug 08, 1:30PM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer, President and Chief Executive Officer, is scheduled to present at the 2016 Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 4:30 p.m. ET. The conference will be held at the InterContinental in Boston, Mass.
ANGO: 16.54 (-0.23)
34.8% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Mon Aug 08, 1:01PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 5 months, Angiodynamics has returned 34.84% as of today's recent price of $15.37.
ANGO: 16.54 (-0.23)
AngioDynamics Announces Secondary Offering of 2,250,000 Shares of Common Stock by Selling Stockholders
GlobeNewswire - Mon Aug 01, 3:30PM CDT
AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Avista Capital Partners, LP and affiliated investment funds intend to offer for sale 2,250,000 shares of common stock in an underwritten secondary offering, pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission ("SEC"
. The selling shareholders will receive all of the net proceeds from the offering. AngioDynamics is not selling any common shares in the offering and will not receive any of the proceeds. Cantor Fitzgerald & Co. will act as underwriter for the offering.
ANGO: 16.54 (-0.23)
Shares of ANGO Up 46.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jul 29, 12:39PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 5 months, Angiodynamics has returned 46.20% as of today's recent price of $16.66.
ANGO: 16.54 (-0.23)
PAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Apr 28, 11:09AM CDT
What:
PAVMU: 14.53 (+0.23), ANGO: 16.54 (-0.23), NDAQ: 71.21 (-0.13)
AngioDynamics Tops Q3 Earnings, Sales; FY16 View Pruned
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 9:00AM CDT
AngioDynamics Inc. (ANGO) reported adjusted earnings of 15 cents per share in the third quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a couple cents.
LMAT: 18.38 (-0.08), AMAG: 23.83 (-0.06), ANGO: 16.54 (-0.23), OFIX: 45.11 (+0.52)
Natus Medical: A Strong Sell on Weak Q1 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 12:00PM CDT
On Apr 7, Zacks Investment Research downgraded Natus Medical Inc (BABY) to a Zacks Rank #5 (Strong Sell).
BABY: 38.91 (-0.62), GMED: 23.23 (+0.15), ARAY: 5.33 (-0.03), ANGO: 16.54 (-0.23)
Mazor Robotics Receives 5 Orders in Q1, Shares Down
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 12:20PM CDT
Shares of Mazor Robotics Ltd. (MZOR) fell 4.1% to close at $11.60 on Apr 5, after the company announced the receipt of five orders for Renaissance system.
GMED: 23.23 (+0.15), MZOR: 22.38 (-0.44), ARAY: 5.33 (-0.03), ANGO: 16.54 (-0.23)
Downgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Apr 06, 3:16AM CDT
Angiodynamics (NASDAQ:ANGO) was downgraded from Buy to Hold at Canaccord Genuity today. The stock closed yesterday at $11.07 on volume of 222,000 shares, above average daily volume of 75,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
ANGO: 16.54 (-0.23)
Can the Uptrend Continue for AngioDynamics (ANGO)?
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:49AM CDT
Investors certainly have to be happy with AngioDynamics, Inc. (ANGO) and its short term performance
ANGO: 16.54 (-0.23)
AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer
GlobeNewswire - Mon Apr 04, 7:00AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of James C. Clemmer as the company's new President and Chief Executive Officer, effective April 4, 2016.
ANGO: 16.54 (-0.23)
AngioDynamics to Report Fiscal 2016 Third Quarter Financial Results
GlobeNewswire - Tue Mar 29, 5:30AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 third quarter ended February 29, 2016, on Thursday, April 7, 2016, after the close of the U.S. financial markets.
ANGO: 16.54 (-0.23)
AngioDynamics: Health Canada Okays Celerity with Navigation
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:20PM CST
AngioDynamics (ANGO) recently announced that Health Canada has approved the company's Celerity PICC Tip Confirmation System with Navigation.
ABMD: 117.94 (-1.40), EXAC: 27.79 (-0.09), LMNX: 21.07 (+0.04), ANGO: 16.54 (-0.23)
Mauna Kea Technologies Announces the Appointment of Joseph DeVivo as a Non-Executive Director
PR Newswire - Mon Jan 11, 11:00AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Joseph M. DeVivo as a Director. Mr. DeVivo is the President and Chief Executive Officer of AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.
ANGO: 16.54 (-0.23)
AngioDynamics Q2 Earnings In Line, Sales Top; '16 View Cut
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:20AM CST
AngioDynamics (ANGO) reported adjusted earnings of 14 cents per share in the second quarter of fiscal 2016, which were in line with the Zacks Consensus Estimate but down 17.6% on a year-over-year basis.
CAPR: 3.66 (+0.06), NXTM: 22.86 (-0.24), ABAX: 50.14 (-0.71), ANGO: 16.54 (-0.23)
AngioDynamics Reports Fiscal 2016 Second Quarter Results
GlobeNewswire - Thu Jan 07, 3:01PM CST
-- Net sales of $89.2 million
ANGO: 16.54 (-0.23)
AngioDynamics to Present at the 34th Annual J.P. Morgan Global Healthcare Conference
GlobeNewswire - Mon Jan 04, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph DeVivo, President and Chief Executive Officer, is scheduled to present at the 34 Annual J.P. Morgan Global Healthcare Conference on Wednesday, January 13, 2016, at 5:30 p.m. EST. The conference will be held at the Westin St. Francis in San Francisco, Ca.
JPM: 67.50 (unch), ANGO: 16.54 (-0.23)
47.2% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Wed Aug 31, 12:17AM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 6 months, Angiodynamics has returned 47.17% as of today's recent price of $16.77.
ANGO: 16.54 (-0.23)
Angiodynamics Shares Up 45.1% Since SmarTrend's Buy Recommendation (ANGO)
Comtex SmarTrend(R) - Tue Aug 23, 12:41PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 6 months, Angiodynamics has returned 45.06% as of today's recent price of $16.53.
ANGO: 16.54 (-0.23)
Angiodynamics Up 40.3% Since SmarTrend Uptrend Call (ANGO)
Comtex SmarTrend(R) - Tue Aug 16, 12:26AM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 5 months, Angiodynamics has returned 40.32% as of today's recent price of $15.99.
ANGO: 16.54 (-0.23)
AngioDynamics to Present at the 2016 Canaccord Genuity Growth Conference
GlobeNewswire - Mon Aug 08, 1:30PM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer, President and Chief Executive Officer, is scheduled to present at the 2016 Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 4:30 p.m. ET. The conference will be held at the InterContinental in Boston, Mass.
ANGO: 16.54 (-0.23)
34.8% Return Seen to Date on SmarTrend Angiodynamics Call (ANGO)
Comtex SmarTrend(R) - Mon Aug 08, 1:01PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 5 months, Angiodynamics has returned 34.84% as of today's recent price of $15.37.
ANGO: 16.54 (-0.23)
AngioDynamics Announces Secondary Offering of 2,250,000 Shares of Common Stock by Selling Stockholders
GlobeNewswire - Mon Aug 01, 3:30PM CDT
AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Avista Capital Partners, LP and affiliated investment funds intend to offer for sale 2,250,000 shares of common stock in an underwritten secondary offering, pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission ("SEC"
. The selling shareholders will receive all of the net proceeds from the offering. AngioDynamics is not selling any common shares in the offering and will not receive any of the proceeds. Cantor Fitzgerald & Co. will act as underwriter for the offering. ANGO: 16.54 (-0.23)
Shares of ANGO Up 46.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jul 29, 12:39PM CDT
SmarTrend identified an Uptrend for Angiodynamics (NASDAQ:ANGO) on March 7th, 2016 at $11.40. In approximately 5 months, Angiodynamics has returned 46.20% as of today's recent price of $16.66.
ANGO: 16.54 (-0.23)
PAVmed Inc. (Nasdaq: PAVMU) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Thu Apr 28, 11:09AM CDT
What:
PAVMU: 14.53 (+0.23), ANGO: 16.54 (-0.23), NDAQ: 71.21 (-0.13)
AngioDynamics Tops Q3 Earnings, Sales; FY16 View Pruned
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 9:00AM CDT
AngioDynamics Inc. (ANGO) reported adjusted earnings of 15 cents per share in the third quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a couple cents.
LMAT: 18.38 (-0.08), AMAG: 23.83 (-0.06), ANGO: 16.54 (-0.23), OFIX: 45.11 (+0.52)
Natus Medical: A Strong Sell on Weak Q1 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 12:00PM CDT
On Apr 7, Zacks Investment Research downgraded Natus Medical Inc (BABY) to a Zacks Rank #5 (Strong Sell).
BABY: 38.91 (-0.62), GMED: 23.23 (+0.15), ARAY: 5.33 (-0.03), ANGO: 16.54 (-0.23)
Mazor Robotics Receives 5 Orders in Q1, Shares Down
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 12:20PM CDT
Shares of Mazor Robotics Ltd. (MZOR) fell 4.1% to close at $11.60 on Apr 5, after the company announced the receipt of five orders for Renaissance system.
GMED: 23.23 (+0.15), MZOR: 22.38 (-0.44), ARAY: 5.33 (-0.03), ANGO: 16.54 (-0.23)
Downgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Apr 06, 3:16AM CDT
Angiodynamics (NASDAQ:ANGO) was downgraded from Buy to Hold at Canaccord Genuity today. The stock closed yesterday at $11.07 on volume of 222,000 shares, above average daily volume of 75,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
ANGO: 16.54 (-0.23)
Can the Uptrend Continue for AngioDynamics (ANGO)?
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:49AM CDT
Investors certainly have to be happy with AngioDynamics, Inc. (ANGO) and its short term performance
ANGO: 16.54 (-0.23)
AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer
GlobeNewswire - Mon Apr 04, 7:00AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of James C. Clemmer as the company's new President and Chief Executive Officer, effective April 4, 2016.
ANGO: 16.54 (-0.23)
AngioDynamics to Report Fiscal 2016 Third Quarter Financial Results
GlobeNewswire - Tue Mar 29, 5:30AM CDT
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2016 third quarter ended February 29, 2016, on Thursday, April 7, 2016, after the close of the U.S. financial markets.
ANGO: 16.54 (-0.23)
AngioDynamics: Health Canada Okays Celerity with Navigation
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 3:20PM CST
AngioDynamics (ANGO) recently announced that Health Canada has approved the company's Celerity PICC Tip Confirmation System with Navigation.
ABMD: 117.94 (-1.40), EXAC: 27.79 (-0.09), LMNX: 21.07 (+0.04), ANGO: 16.54 (-0.23)
Mauna Kea Technologies Announces the Appointment of Joseph DeVivo as a Non-Executive Director
PR Newswire - Mon Jan 11, 11:00AM CST
Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the appointment of Joseph M. DeVivo as a Director. Mr. DeVivo is the President and Chief Executive Officer of AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology.
ANGO: 16.54 (-0.23)
AngioDynamics Q2 Earnings In Line, Sales Top; '16 View Cut
Zacks Equity Research - Zacks Investment Research - Fri Jan 08, 8:20AM CST
AngioDynamics (ANGO) reported adjusted earnings of 14 cents per share in the second quarter of fiscal 2016, which were in line with the Zacks Consensus Estimate but down 17.6% on a year-over-year basis.
CAPR: 3.66 (+0.06), NXTM: 22.86 (-0.24), ABAX: 50.14 (-0.71), ANGO: 16.54 (-0.23)
AngioDynamics Reports Fiscal 2016 Second Quarter Results
GlobeNewswire - Thu Jan 07, 3:01PM CST
-- Net sales of $89.2 million
ANGO: 16.54 (-0.23)
AngioDynamics to Present at the 34th Annual J.P. Morgan Global Healthcare Conference
GlobeNewswire - Mon Jan 04, 5:30AM CST
AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph DeVivo, President and Chief Executive Officer, is scheduled to present at the 34 Annual J.P. Morgan Global Healthcare Conference on Wednesday, January 13, 2016, at 5:30 p.m. EST. The conference will be held at the Westin St. Francis in San Francisco, Ca.
JPM: 67.50 (unch), ANGO: 16.54 (-0.23)
